Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Siemens Healthineers, Precipio Diagnostics, Transgenomic, Orig3n, and More

NEW YORK (360Dx) – Siemens Healthineers said Friday that it has broken ground on a "major expansion" of one of the company's manufacturing R&D facilities for laboratory diagnostics in Walpole, Massachusetts.

The firm said that through the expansion, which required a $300 million investment, the firm would create up to 700 new high-tech jobs over the next 10 years. It noted that expanding the manufacturing facility "exemplifies the company’s broader strategy for creating local value" in the US, its largest market.


Precipio Diagnostics and Transgenomic have completed their previously announced merger. Under the deal, Omaha, Nebraska-based Transgenomic will be merged into Precipio, which is based in New Haven, Connecticut and offers molecular diagnostic tests for cancer, and Transgenomic's CLIA-certified lab will move to the New Haven location. Precipio CEO Ilan Danieli will keep that post in the combined company. The new firm is expected to begin trading on the Nasdaq on June 30 under the ticker symbol "PRPO".


Orig3n has raised $20 million in a recent round of private financing. The Boston-based firm offers direct-to-consumer genetic tests and is developing regenerative medicine projects. A spokesperson said Orig3n will use proceeds from the financing to expand its research into cell therapies.

Hatteras Venture Partners led the round of financing, which included previous investors in the firm LabCorp, Syno Capital, KTB-KORUS Fund, MGC Venture Partners, DEFTA Partners, and 180 Degree Capital, and new investor Spectrum Health Ventures. Orig3n also said that Byron Smith, a principal at Mountain Group Partners, has joined the firm's board of directors.


Sera Prognostics has received accreditation from the College of American Pathologists, based on a recent onsite inspection, during which inspectors examined the lab’s records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management as part of the process.


MetaStat has raised around $2.1 million of a planned $7.0 million in a private placement of its common stock led by Perceptive Advisors, along with existing institutional and accredited investors. The Boston-based molecular diagnostics and therapeutics developer said the placement consisted of an aggregate of 690,816 shares of common stock and approximately 196,216 shares of Series A-2 convertible preferred stock, which are convertible into 1,962,164 shares of common stock. In connection with the private placement, the company adjusted the exercise price of 474,829 outstanding common stock purchase warrants from $3.00 per share to $2.00 per share. The firm said it has until the end of July to complete the placement.


SenzaGen and Charles River Laboratories signed a global distribution agreement to market SenzaGen’s genetic Gardskin chemical skin sensitivity test. The test is based on biomarkers for more than 200 genes covering the entire immune reaction to predict the risk of hypersensitivity. Financial and other terms of the deal were not disclosed.


Biocept has been added to the Russell Microcap Index, which includes 1,000 of the smallest securities in the Russell 2000 Index by market capitalization. Among the other firms in the Microcap index are HTG Molecular Diagnostics and Natera. 


According to Virginia Gov. Terry McAuliffe, Thermo Fisher Scientific will spend $9.5 million expanding its clinical diagnostic operation in Frederick County, Virginia, and it plans to create 57 new jobs.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.